Dendreon Corporation to Present Data on Immunotherapy Programs at American Association for Cancer Research Annual Meeting.

Business Editors/Health/Medical Writers

BIOWIRE2K

95th Annual Meeting of the American Association for

Cancer Research (AACR)

SEATTLE--(BUSINESS WIRE)--March 26, 2004

Dendreon Corporation (Nasdaq:DNDN) today announced the scheduled presentation of two abstracts at the 95th Annual Meeting of the American Association for Cancer Research (AACR), March 27-31, 2004 in Orlando, Florida. Researchers will present data on Provenge(R), currently in Phase 3 clinical trials for prostate cancer, and APC8024, currently in Phase 1 clinical trials for advanced, metastatic, Her-2/neu positive breast cancer.

Abstract Presentations:

-- Sunday, March 28, 2004; 2:45 p.m. - 3:45 p.m.; Room W315:

Poster Discussion Session. (Abstract #1408). A

placebo-controlled Phase 3 trial of immunotherapy (APC8015,

Provenge(R)) for androgen independent prostate cancer (AIPC):

Evidence that Gleason Score predicts immunologic as well as

clinical responses to therapy.

-- Sunday, March 28, 2004; 1 p.m. - 5 p.m.; Hall B4-D: Poster

Session. (Abstract #1229). (APC8024) Phase 1 study using

autologous antigen presenting cells loaded with BA7072 to

treat subjects with metastatic breast cancer that over

expresses HER-2/neu.

Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody, small molecule and prodrug product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks associated with completing Dendreon's clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support further clinical trials or an application for a biologics license, the risk that the FDA will not approve a product for which a biologics license has been applied, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property, Dendreon's limited operating history and risks related to the uncertainty of Dendreon's future access to capital. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.